These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26442452)

  • 1. The NINDS Parkinson's disease biomarkers program.
    Rosenthal LS; Drake D; Alcalay RN; Babcock D; Bowman FD; Chen-Plotkin A; Dawson TM; Dewey RB; German DC; Huang X; Landin B; McAuliffe M; Petyuk VA; Scherzer CR; Hillaire-Clarke CS; Sieber BA; Sutherland M; Tarn C; West A; Vaillancourt D; Zhang J; Gwinn K;
    Mov Disord; 2016 Jun; 31(6):915-23. PubMed ID: 26442452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.
    Kang UJ; Goldman JG; Alcalay RN; Xie T; Tuite P; Henchcliffe C; Hogarth P; Amara AW; Frank S; Rudolph A; Casaceli C; Andrews H; Gwinn K; Sutherland M; Kopil C; Vincent L; Frasier M
    Mov Disord; 2016 Jun; 31(6):924-32. PubMed ID: 27113479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease biomarkers program brain imaging repository.
    Ofori E; Du G; Babcock D; Huang X; Vaillancourt DE
    Neuroimage; 2016 Jan; 124(Pt B):1120-1124. PubMed ID: 25976927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.
    Gwinn K; David KK; Swanson-Fischer C; Albin R; Hillaire-Clarke CS; Sieber BA; Lungu C; Bowman FD; Alcalay RN; Babcock D; Dawson TM; Dewey RB; Foroud T; German D; Huang X; Petyuk V; Potashkin JA; Saunders-Pullman R; Sutherland M; Walt DR; West AB; Zhang J; Chen-Plotkin A; Scherzer CR; Vaillancourt DE; Rosenthal LS
    Biomark Med; 2017 May; 11(6):451-473. PubMed ID: 28644039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
    Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.
    Elm JJ;
    Mov Disord; 2012 Oct; 27(12):1513-21. PubMed ID: 23079770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort.
    Lawton M; Baig F; Toulson G; Morovat A; Evetts SG; Ben-Shlomo Y; Hu MT
    Mov Disord; 2020 Feb; 35(2):279-287. PubMed ID: 31693246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis.
    Eusebi P; Hansson O; Paciotti S; Orso M; Chiasserini D; Calabresi P; Blennow K; Parnetti L
    BMJ Open; 2017 Nov; 7(11):e018177. PubMed ID: 29170290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease.
    Bloem BR; Marks WJ; Silva de Lima AL; Kuijf ML; van Laar T; Jacobs BPF; Verbeek MM; Helmich RC; van de Warrenburg BP; Evers LJW; intHout J; van de Zande T; Snyder TM; Kapur R; Meinders MJ
    BMC Neurol; 2019 Jul; 19(1):160. PubMed ID: 31315608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRNA-derived fragments as sex-dependent circulating candidate biomarkers for Parkinson's disease.
    Magee R; Londin E; Rigoutsos I
    Parkinsonism Relat Disord; 2019 Aug; 65():203-209. PubMed ID: 31402278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
    Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
    Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Espay AJ; Schwarzschild MA; Tanner CM; Fernandez HH; Simon DK; Leverenz JB; Merola A; Chen-Plotkin A; Brundin P; Kauffman MA; Erro R; Kieburtz K; Woo D; Macklin EA; Standaert DG; Lang AE
    Mov Disord; 2017 Mar; 32(3):319-324. PubMed ID: 28233927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1.
    Wills AM; Pérez A; Wang J; Su X; Morgan J; Rajan SS; Leehey MA; Pontone GM; Chou KL; Umeh C; Mari Z; Boyd J;
    JAMA Neurol; 2016 Mar; 73(3):321-8. PubMed ID: 26751506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
    Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P;
    BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.